NASDAQ:LTRN

Lantern Pharma Reports First Quarter 2024 Financial Results and Business Highlights

Retrieved on: 
Thursday, May 9, 2024
Technology, Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Artificial Intelligence, Oncology

Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical-stage drug programs, today announced operational highlights and financial results for the first quarter 2024, ended March 31, 2024.

Key Points: 
  • Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical-stage drug programs, today announced operational highlights and financial results for the first quarter 2024, ended March 31, 2024.
  • The company expects to open additional sites in the US throughout the second quarter with the potential to advance to Phase 1b/2 by the close of 2024.
  • Lantern expects to pursue additional biopharma and technology partnerships during 2024 to further advance and commercialize the RADR® AI platform.
  • Earnings Call and Webinar Details:
    Lantern will host its 1st quarter 2024 earnings call and webinar today, May 9, 2024, at 4:30 p.m.

Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism

Retrieved on: 
Monday, May 6, 2024
Data Management, Biotechnology, Technology, Health, Pharmaceutical, Oncology, Health Technology, Other Technology, Software, Artificial Intelligence, Clinical Trials, Enzyme, Cancer, Prostate, IP, D.C, PDI, Proteinopathy, PMID, Drug resistance, Machine learning, The Journal of Pathology, Breast, MD, Cell, Artificial intelligence, Leukemia, ISSN, Cancer Medicine, Molecular biology, CNS, Giaquinto, Algorithm, Patient, Neoplasm, Lung, Death, Head, Biomarker, Drug development, Therapy, Clinician, Journal, Ovarian cancer, Brain, Oncology Reports, Pharmaceutical industry

(NASDAQ: LTRN), a leading artificial intelligence (AI) oncology drug discovery and development company, today announced a strategic AI-driven collaboration with French biotechnology company, Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase (PDI) (1) inhibitor drug candidate XCE853 in novel and targeted cancer indications.

Key Points: 
  • (NASDAQ: LTRN), a leading artificial intelligence (AI) oncology drug discovery and development company, today announced a strategic AI-driven collaboration with French biotechnology company, Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase (PDI) (1) inhibitor drug candidate XCE853 in novel and targeted cancer indications.
  • Oregon Therapeutics is developing XCE853 in various cancer indications, including drug-resistant ovarian and pancreatic cancer, certain hematological cancers and several pediatric cancers including CNS cancers.
  • Oregon Therapeutic’s lead drug-candidate XCE853 is known to target PDIs of specific interest for cancer.
  • Oregon Therapeutics is entitled to financial benefits resulting from the out licensing of the background IP to Lantern Pharma.

Lantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4:30 p.m. ET

Retrieved on: 
Thursday, May 2, 2024
Biotechnology, Technology, Health, Pharmaceutical, Oncology, Other Science, Research, Software, Artificial Intelligence, Science, Clinical Trials, Machine learning, A.I, Artificial intelligence, Zoom

Management intends to discuss the operating and financial results for the first quarter of 2024 and provide guidance on upcoming milestones, clinical trials, and developments of the A.I.

Key Points: 
  • Management intends to discuss the operating and financial results for the first quarter of 2024 and provide guidance on upcoming milestones, clinical trials, and developments of the A.I.
  • Panna Sharma, President and Chief Executive Officer of Lantern Pharma, will lead the call and will be joined by other members of the management team.
  • To register for the webinar, please sign up at the Zoom webcast link provided in the link: Lantern Pharma Q1 2024 earnings Zoom webcast registration link .
  • A replay of the earnings call webcast will be available after the call on the investor relations section of the Company's website: ir.lanternpharma.com .

Lantern Pharma Launches “Webinar Wednesdays” Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development

Retrieved on: 
Wednesday, April 24, 2024
Health, Pharmaceutical, Technology, Artificial Intelligence, Oncology, Brain, Fox Chase Cancer Center, AIDS, Lung cancer, AI, Pancreatic cancer, Ambulatory care, Hematology, Machine learning, MD, Doctor of Philosophy, National Cancer Institute, Research, Ohio State University, Artificial intelligence, Disease, Science, Patient, NCI, Physician, Neoplasm, Central nervous system, Diagnosis, Drug development, Associate, Sanofi, Kishor, Medical director, AstraZeneca, Pharmaceutical industry

The series begins today, Wednesday, April 24, 2024, and is planned to be held on the last Wednesday of each month.

Key Points: 
  • The series begins today, Wednesday, April 24, 2024, and is planned to be held on the last Wednesday of each month.
  • Each webinar will feature a presentation from a Lantern collaborator, advisor, or researchers followed by a live Q&A.
  • These sessions provide a deep dive into the company’s research, collaborations, clinical trials and expected goals for the drug or AI development initiatives.
  • Igor Astsaturov, MD is a leading expert in pancreatic cancer collaborating with Lantern Pharma on the LP-184 clinical trial.

Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan

Retrieved on: 
Monday, April 22, 2024
Technology, Clinical Trials, Health Technology, Software, Biotechnology, Pharmaceutical, Health, Data Management, Oncology, Artificial Intelligence, Education, National Cancer Center, MET, D.C, Lung cancer, Woman, PMID, Progression-free survival, Harmonic, Machine learning, AME Publishing Company, ClinicalTrials.gov, Collection, Artificial intelligence, IPhone, Adenocarcinoma, ROS1, Disease, Incidence, Patient, Pemetrexed, TMB, SOC, Neoplasm, Lung, ALK, EGFR, NSCLC, Carboplatin, Overalls, Gene, TK, Pharmaceutical industry

Approximately one third of all lung cancer patients in East Asia are never-smokers and the proportion of lung cancer in never smokers (LCINS) has been increasing gradually over time, according to a publication in Translational Lung Cancer Research (1).

Key Points: 
  • Approximately one third of all lung cancer patients in East Asia are never-smokers and the proportion of lung cancer in never smokers (LCINS) has been increasing gradually over time, according to a publication in Translational Lung Cancer Research (1).
  • LCINS are histologically, mutationally, and epidemiologically distinct from smoking-related lung cancers and occur almost exclusively as adenocarcinomas and most commonly in women and individuals of Asian ancestry.
  • Dr. Goto will now lead the trial in Japan, where the incidence of non-small cell lung cancer (NSCLC) in never-smokers is double or more than that of the United States.
  • In addition, LP-300 has been administered in multiple clinical trials to more than 1,000 people and has been generally well tolerated.

Global A.I. Medical Diagnostics Market Poised To Reach $3.7 Billion By 2028

Retrieved on: 
Wednesday, March 20, 2024
Tendinopathy, Artificiality, Health, Patient, Conditional sentence, History, Artificial intelligence, Lantern, Mantle cell lymphoma, OTCQX, Microsoft HoloLens, Context, Corporation, NEO, Microsoft, Automation, MCL, DHL, Splenic infarction, Diabetes, Risk, PALM, Radiology, Software, Treatment, UiPath, OTCQB, Strategic alliance, Prevalence, Disease, Microsoft Mesh, Hospital, Research, News, WELL, Student, TSX, MPH, Nursing, Machine learning, Diagnosis, TED (conference), OSCE, Growth, Cancer, Trust, Sarcoma, NHL, Appendicitis, Ecosystem, Probability, AIDX, Medical device

A report from MarketsAndMarkets opined that the global AI in medical diagnostics market in terms of revenue was estimated to be worth $1.3 billion in 2023 and is poised to reach $3.7 billion by 2028, growing at a CAGR of 23.2% from 2023 to 2028.

Key Points: 
  • A report from MarketsAndMarkets opined that the global AI in medical diagnostics market in terms of revenue was estimated to be worth $1.3 billion in 2023 and is poised to reach $3.7 billion by 2028, growing at a CAGR of 23.2% from 2023 to 2028.
  • MarketsAndMarkets continued: “Based on component, the AI in medical diagnostics market is bifurcated into software, services, and hardware.
  • The software segment accounted for the largest share of the global AI in medical diagnostics Market in 2022.
  • The hospitals segment accounted for the largest share of the global AI in medical diagnostics Market in 2022.

Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights

Retrieved on: 
Monday, March 18, 2024
Research, Technology, Clinical Trials, Biotechnology, Pharmaceutical, Health, Science, Oncology, Artificial Intelligence, Other Science, Lymphoma, Patient, GBM, Artificial intelligence, Brain, Metadata, Pancreatic cancer, Lung cancer, Mantle cell lymphoma, Clinical trial, Therapy, Harmonic, ATM, USD, PD-1, MCL, DHL, Central nervous system, CNS, DNA, Starlight, Fox Chase Cancer Center, Glioblastoma, Cancer, Safety, Liquid biopsy, Calendar, ADC, TP53, NSCLC, ATRT, AI, AACR, Drug development, Machine learning, FDA, Annual general meeting, Incidence, Triple-negative breast cancer, NHL, Patent, Pharmaceutical industry

“This past quarter and the entire year of 2023 was a period of meaningful and remarkable progress for our programs and our AI platform at Lantern Pharma.

Key Points: 
  • “This past quarter and the entire year of 2023 was a period of meaningful and remarkable progress for our programs and our AI platform at Lantern Pharma.
  • During the 4th quarter of 2023, Lantern filed 3 new patent applications culminating in 11 new patent applications for the calendar year 2023.
  • The cash burn rate for the 4th quarter and full year of 2023 continues to reflect our capital-efficient, collaborator-centered business model.
  • Full Year Net Loss: Net loss per share was $1.47 per share for the fiscal year 2023 compared to $1.31 per share for the fiscal year 2022.

Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284

Retrieved on: 
Friday, March 15, 2024
Technology, Clinical Trials, Health Technology, Software, Biotechnology, Pharmaceutical, Health, Data Management, Oncology, Artificial Intelligence, SOC, MCL, Index, DHL, Patient, Neoplasm, Artificial intelligence, AI, Sarcoma, Human, NHL, Mantle cell lymphoma, Clinical trial, Bone marrow, Safety, Pharmacokinetics, MTD, Machine learning, FDA, DLBCL, Pharmaceutical industry

“Enrolling and treating initial patients in our Phase 1 trial for LP-284 is a major milestone and underscores the commitment of our team to advancing our pipeline of AI-driven therapies to patients,” stated Panna Sharma, Lantern's President and CEO.

Key Points: 
  • “Enrolling and treating initial patients in our Phase 1 trial for LP-284 is a major milestone and underscores the commitment of our team to advancing our pipeline of AI-driven therapies to patients,” stated Panna Sharma, Lantern's President and CEO.
  • Patients will be enrolled and treated with LP-284 administered intravenously (IV) on Days 1, 8, 15 of a 28-day schedule.
  • Up to 30 patients will be enrolled in Phase 1a; the total number of patients will depend on the number of dose levels explored.
  • Additionally, Lantern may enroll up to 40 patients in each of the two cohorts of MCL and HGBL (including DLBCL) tumors in Phase 1b.

Lantern Pharma to Report Fourth Quarter and Fiscal Year 2023 Operating & Financial Results on March 18th, 2024 at 4:30 p.m. ET

Retrieved on: 
Monday, March 11, 2024
Oncology, Health, Technology, General Health, Clinical Trials, Artificial Intelligence, Biotechnology, A.I, Machine learning, Artificial intelligence, Zoom, Pharmaceutical industry

Management intends to discuss the operating and financial results for the fourth quarter and fiscal year ended December 31, 2023 and provide guidance on upcoming milestones, clinical trials and developments of the A.I.

Key Points: 
  • Management intends to discuss the operating and financial results for the fourth quarter and fiscal year ended December 31, 2023 and provide guidance on upcoming milestones, clinical trials and developments of the A.I.
  • Panna Sharma, President and Chief Executive Officer of Lantern Pharma, will lead the call and will be joined by other members of the management team.
  • To register for the webinar, please sign up at the Zoom webcast link provided in the link: Lantern Pharma Q4 2023 earnings Zoom webcast registration link .
  • A replay of the earnings call webcast will be available after the call on the investor relations section of the Company's website: ir.lanternpharma.com .

Lantern To Participate in H.C Wainwright & Co.’s (HCW) 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference

Retrieved on: 
Tuesday, March 5, 2024
Oncology, Health, Technology, Artificial Intelligence, Pharmaceutical, Biotechnology, HCW, Drug discovery, Artificial intelligence, Conference, Pharmaceutical industry

Lantern Pharma Inc. (NASDAQ: LTRN), a leader in AI-driven cancer drug discovery and development, announced that it will be presenting at a virtual conference being hosted by HCW.

Key Points: 
  • Lantern Pharma Inc. (NASDAQ: LTRN), a leader in AI-driven cancer drug discovery and development, announced that it will be presenting at a virtual conference being hosted by HCW.
  • The conference will be on Thursday, March 7th, and is a virtual event.
  • Lantern Pharma’s CEO, Mr. Panna Sharma, will be discussing and presenting via a fireside chat format at The 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference at approximately 2 pm Eastern / 11 am Pacific.
  • While addressing AI in drug discovery, Mr. Sharma will talk about how RADR®, Lantern’s proprietary AI platform, is transforming the cost, pace, and timeline of oncology drug development.